Skip to Main Content

Paper Details

Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.
Clin Cancer Res
10
2022
-V7, AR, AR splice variant-7, AR-, AR-V7, AR-V7 antibody, AR-V7 mRNA, Androgen, Androgen Receptor Splice Variant-7, CRPC, CRPC PDX models, CSPC, Castration-Sensitive Prostate Cancer, EPR15656 AR-V7 antibody, RM7, V7, V7 mRNA, V7 protein, androgen, androgen receptor, castration-resistant prostate cancer, castration-sensitive prostate cancer, patient, patient-derived xenograft (PDX) models, patients, prostate cancer, prostate cancer cell lines, splice boundaries
Author NameAffiliation
Adam G SowalskyCenter for Cancer Research
Rosina T LisCenter for Cancer Research
Ilsa ColemanFred Hutchinson Cancer Research Center
Wei YuanInstitute of Cancer Research
Lawrence D TrueUniversity of Washington
Steven P BalkBeth Israel Deaconess Medical Center
Eva CoreyUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington
Michael C HaffnerFred Hutchinson Cancer Research Center
Michael C HaffnerUniversity of Washington
Stephen R PlymateUniversity of Washington
Stephen R PlymateEducation and Clinical Center
Johann S de BonoInstitute of Cancer Research
Johann S de BonoRoyal Marsden NHS Foundation Trust
Adam SharpInstitute of Cancer Research
Adam SharpRoyal Marsden NHS Foundation Trust
  • 1 - 19

Datasets

Release 1.2